Cargando…

General evaluation score for predicting the development of hepatocellular carcinoma in patients with advanced liver fibrosis associated with hepatitis C virus genotype 1 or 2 after direct‐acting antiviral therapy

BACKGROUND AND AIM: To validate a composite predictive model for hepatocellular carcinoma (HCC) development in patients with advanced liver fibrosis associated with chronic hepatitis C virus (HCV) who have received direct‐acting antiviral (DAA) therapy and achieved sustained virologic response (SVR)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tada, Toshifumi, Kurosaki, Masayuki, Tamaki, Nobuharu, Yasui, Yutaka, Mori, Nami, Tsuji, Keiji, Hasebe, Chitomi, Joko, Koji, Akahane, Takehiro, Furuta, Koichiro, Kobashi, Haruhiko, Fujii, Hideki, Ishii, Toru, Marusawa, Hiroyuki, Kondo, Masahiko, Kojima, Yuji, Yoshida, Hideo, Uchida, Yasushi, Nakamura, Shinichiro, Izumi, Namiki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Publishing Asia Pty Ltd 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260214/ https://www.ncbi.nlm.nih.gov/pubmed/35822118 http://dx.doi.org/10.1002/jgh3.12778

Ejemplares similares

A validation study of after direct‐acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct‐acting antiviral therapy and achieved sustained virological response
por: Tada, Toshifumi, et al.
Publicado: (2021)

Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus
por: Tamaki, Nobuharu, et al.
Publicado: (2021)

Necessity for surveillance for hepatocellualr carcinoma in older patients with chronic hepatitis C who achieved sustained virological response
por: Ishido, Shun, et al.
Publicado: (2023)

Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score
por: Kaneko, Shun, et al.
Publicado: (2020)

Real‐world long‐term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection
por: Fujii, Hideki, et al.
Publicado: (2022)

Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study
por: Yasui, Yutaka, et al.
Publicado: (2022)

The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study
por: Tsuchiya, Kaoru, et al.
Publicado: (2021)

Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C
por: Itakura, Jun, et al.
Publicado: (2020)

Real‐world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group
por: Mashiba, Toshie, et al.
Publicado: (2019)

Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases
por: Tamaki, Nobuharu, et al.
Publicado: (2021)

Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure
por: Itakura, Jun, et al.
Publicado: (2016)

Irregular vascular pattern by contrast‐enhanced ultrasonography and high serum Lens culinaris agglutinin‐reactive fraction of alpha‐fetoprotein level predict poor outcome after successful radiofrequency ablation in patients with early‐stage hepatocellular carcinoma
por: Takada, Hitomi, et al.
Publicado: (2016)

Use of the Serum Wisteria floribunda Agglutinin-Positive Mac2 Binding Protein as a Marker of Gastroesophageal Varices and Liver-Related Events in Chronic Hepatitis C Patients
por: Hayashi, Tsuguru, et al.
Publicado: (2020)

Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group
por: Mashiba, Toshie, et al.
Publicado: (2018)

Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy
por: Itakura, Jun, et al.
Publicado: (2015)

Genetic Polymorphisms of IL28B and PNPLA3 Are Predictive for HCV Related Rapid Fibrosis Progression and Identify Patients Who Require Urgent Antiviral Treatment with New Regimens
por: Tamaki, Nobuharu, et al.
Publicado: (2015)

Serum Wisteria Floribunda Agglutinin-Positive Sialylated Mucin 1 as a Marker of Progenitor/Biliary Features in Hepatocellular Carcinoma
por: Tamaki, Nobuharu, et al.
Publicado: (2017)

Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma
por: Takada, Hitomi, et al.
Publicado: (2018)

Tolvaptan for the Treatment of Refractory Ascites
por: Kurosaki, Masayuki, et al.
Publicado: (2016)

Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio
por: Komiyama, Yasuyuki, et al.
Publicado: (2017)

Pretreatment Gastric Lavage Reduces Postoperative Bleeding after Endoscopic Submucosal Dissection for Gastric Neoplasms
por: Nakanishi, Hiroyuki, et al.
Publicado: (2016)

Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures
por: Takada, Hitomi, et al.
Publicado: (2019)

New diagnostic technique to evaluate hepatic steatosis using the attenuation coefficient on ultrasound B mode
por: Koizumi, Yohei, et al.
Publicado: (2019)

Predictors of Virological Response to a Combination Therapy with Pegylated Interferon Plus Ribavirin Including Virus and Host Factors
por: Izumi, Namiki, et al.
Publicado: (2010)

Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma
por: Tsuchiya, Kaoru, et al.
Publicado: (2014)

Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease
por: Tamaki, Nobuharu, et al.
Publicado: (2019)

Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein but not α-Fetoprotein as a Long-Term Hepatocellular Carcinoma Predictor
por: Osawa, Leona, et al.
Publicado: (2020)

Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis
por: Inada, Kento, et al.
Publicado: (2021)

The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy
por: Takaura, Kenta, et al.
Publicado: (2022)

Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease
por: Ishido, Shun, et al.
Publicado: (2023)

Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma
por: Yasui, Yutaka, et al.
Publicado: (2016)

Correction: Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma
por: Yasui, Yutaka, et al.
Publicado: (2016)

Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir
por: Tamaki, Nobuharu, et al.
Publicado: (2019)

Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein as a Screening Tool for Significant Liver Fibrosis in Health Checkup
por: Tamaki, Nobuharu, et al.
Publicado: (2020)

Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy
por: Sekiguchi, Shuhei, et al.
Publicado: (2022)

Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis B
por: Ishido, Shun, et al.
Publicado: (2023)

Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib
por: Sakai, Kazuko, et al.
Publicado: (2015)

Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma
por: Takada, Hitomi, et al.
Publicado: (2019)

Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma
por: Kirino, Sakura, et al.
Publicado: (2020)

Early radiological response evaluation with response evaluation criteria in solid tumors 1.1 stratifies survival in hepatocellular carcinoma patients treated with lenvatinib
por: Kaneko, Shun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m1dm8871ur2ipdnoc86sqhpk2k